Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | fused N-acetyl glucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyl transferase | Starlite/ChEMBL | References |
Homo sapiens | aurora kinase B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | aurora kinase B | 303 aa | 299 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | serine:threonine protein kinase 12 B | 0.0068 | 0 | 0.5 |
Plasmodium falciparum | serine/threonine protein kinase, putative | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine- protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase 12 B | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine-protein kinase 6 | 0.0068 | 0 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-2B, gamma subunit, putative | 0.0125 | 0.0931 | 1 |
Leishmania major | protein kinase, putative | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0068 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0684 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0068 | 0 | 0.5 |
Treponema pallidum | licC protein (licC) | 0.0125 | 0.0931 | 0.5 |
Plasmodium vivax | serine/threonine protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Trypanosoma brucei | aurora B kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Giardia lamblia | Aurora kinase | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine kinase 12 | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine protein kinase 6 | 0.0068 | 0 | 0.5 |
Echinococcus multilocularis | aurora kinase A | 0.0068 | 0 | 0.5 |
Trypanosoma cruzi | aurora B kinase, putative | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine- protein kinase 6 , putative | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | protein kinase , putative | 0.0068 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0068 | 0 | 0.5 |
Echinococcus granulosus | aurora kinase A | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Schistosoma mansoni | protein kinase | 0.0068 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | 0.0684 | 1 | 0.5 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | 0.0684 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0068 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.275 uM | Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | = 1.3 uM | Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after 30 mins by malachite green staining-based assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.